Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220460 | 0.91 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5770131 | 0.91 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5768907 | 0.83 | GABRA1 (0.32) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL6218692 | 0.72 | BACE1 (0.40) | — | |
| SCHEMBL5772782 | 0.71 | CYP19A1 (0.32) | — | |
| SCHEMBL23089396 | 0.70 | CYP11B1 (0.35) | — | |
| SCHEMBL23162752 | 0.68 | PTGS2 (0.34) | — | |
| SCHEMBL376385 | 0.67 | ADORA3 (0.39) | — | |
| SCHEMBL22591257 | 0.67 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL30705250 | 0.67 | PRMT5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383768-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-09-06 | — | — | EP | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6642229-B2 | Treatment of adverse neurological conditions | MERCK SHARP & DOHME LTD. | 2003-11-04 | — | — | US | disclosed |